Meta-analysis of ciltacabtagene autoleucel versus physician’s choice therapy for the treatment of patients with relapsed or refractory multiple myeloma

References

• Dimopoulos MA, Richardson PG, Moreau P, et al. Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol. 2015;12(1):42–54.
   PubMed Web of Science ®Google Scholar
• Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266–2275.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk‐stratification and management. Am J Hematol. 2020;95(5):548–567.
   PubMed Web of Science ®Google Scholar
• Mehra M, Vogel M, Valluri S, et al. Patient characteristics, treatment patterns and outcomes in patients with triple class refractory multiple myeloma Abstract #EP1032. Poster presented at: European Hematology Association (EHA) Congress; 2021 Jun 11–14; Virtual.
   Google Scholar
• Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a BCMA-directed CAR T-cell therapy in patients with relapsed/refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314–324.
   PubMed Web of Science ®Google Scholar
• Usmani S, Berdeja J, Madduri D, et al. Updated CARTITUDE-1 results of ciltacabtagene autoleucel, a b-cell maturation antigen–directed chimeric antigen receptor t cell therapy, in relapsed/refractory multiple myeloma Abstract #EP964. Presented at: European Hematology Association (EHA) Congress; 2021 Jun 9–17; Virtual.
   Google Scholar
• Janssen. U.S. FDA Approves CARVYKTI™ (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma. February 28, 2022. [cited 2022 Mar 1]. Available from: https://www.janssen.com/us-fda-approves-carvykti-ciltacabtagene-autoleucel-janssens-first-cell-therapy-bcma-directed-car-t
   Google Scholar
• Weisel K, Martin T, Krishnan A, et al. Comparative efficacy of ciltacabtagene autoleucel in CARTITUDE-1 vs physician’s choice of therapy in the long-term follow-up of POLLUX, CASTOR, and EQUULUES clinical trials for the treatment of patients with relapsed or refractory multiple myeloma. Clin Drug Investig. 2022;42(1):29–41.
   PubMed Web of Science ®Google Scholar
• Costa LJ, Lin Y, Cornell RF, et al. Comparison of cilta-cel, an anti-BCMA CAR-T cell therapy, versus conventional treatment in patients with relapsed/refractory multiple myeloma. Clin Lymphoma Myeloma Leukemia. 2021;22(5):326–335.
   PubMed Web of Science ®Google Scholar
• Merz M, Goldschmidt H, Hari P, et al. Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to PI, imid and anti-CD-38 from a German Registry. Cancers. 2021;13(23):5996.
   PubMed Web of Science ®Google Scholar
• Goldschmidt H, Merz M, Hari P, et al. Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to PI, IMiD and anti-CD-38 from a German registry. Abstract #EP972. Poster presented at: European Hematology Association (EHA) Congress; 2021 Jun 9–17; Virtual.
   Google Scholar
• Mateos M-V, Weisel K, Martin T, et al. Ciltacabtagene autoleucel for triple-class exposed multiple myeloma: adjusted comparisons of CARTITUDE-1 patient outcomes versus therapies from real-world clinical practice from the LocoMMotion prospective study. Abstract #550 presented at: 63rd American Society of Hematology (ASH) Annual Meeting & Exposition; 2021 December 11–14; Virtual 2021.
   Google Scholar
• Martin T, Krishnan A, Yong K, et al. Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician’s choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma. eJHaem. 2022;3(1):97–108.
   PubMedGoogle Scholar
• Deeks JJ, Higgins JP, Altma DG. 10.4.3 Which effect measure for dichotomous outcomes? In: Higgins J, Thomas J, editors. Cochrane handbook for systematic reviews of interventions. Cochrane Statistical Methods Group. NJ: Wiley. 2021.
   Google Scholar
• Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758–764.
   PubMed Web of Science ®Google Scholar
• Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments Meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012;3(2):80–97.
   PubMed Web of Science ®Google Scholar
• Funk MJ, Westreich D, Wiesen C, et al. Doubly robust estimation of causal effects. Am J Epidemiol. 2011;173(7):761–767.
   PubMed Web of Science ®Google Scholar
• Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samples. Stat Med. 2009;28(25):3083–3107.
   PubMed Web of Science ®Google Scholar
• Borenstein M, Hedges LV, Higgins JP, et al. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1(2):97–111.
   PubMed Web of Science ®Google Scholar
• Fisher Z, Tipton E. robumeta: an R-package for robust variance estimation in meta-analysis. arXiv preprint arXiv:150302220. 2015.
   Google Scholar
• Li F, Morgan KL, Zaslavsky AM. Balancing covariates via propensity score weighting. J Am Stat Assoc. 2018;113(521):390–400.
   Web of Science ®Google Scholar
• Backenroth D. How to choose a time zero for patients in external control arms. Pharm Stat. 2021;20(4):783–792.
   PubMed Web of Science ®Google Scholar